Nationwide retrospective cohort study finds TMP-SMX has similar safety to fluoroquinolones in treating uncomplicated cystitis, suggesting its use as a first-line option.
Short-term use of TMP-SMX was not associated with increased risks of adverse events or treatment failure compared with fluoroquinolones. TMP-SMX may represent a reasonable first-line option for acute uncomplicated cystitis in Japan.
No takes yet. Share an insight, caveat, or question.
Taniguchi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: